Table 3.

Comprehensive list of PD-L1 inhibitors and PD-1 inhibitors with antibody class and immune adverse events. This table shows the similarities and differences between PD-1/PD-L1 inhibitors

Target	Drugs	Antibody class	Immune-related adverse events
PD-L1	Atezolizumab	IgG1	Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), meningitis/encephalitis, pancreatitis, dermatitis/rash
	Durvalumab	IgG1	Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), nephritis
	Avelumab	IgG1	Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction
	Envafolimab	IgG1	Increased aspartate aminotransferase, increased alanine aminotransferase, lymphopenia
	BMS-936559	IgG4	Hypothyroidism, hepatitis, sarcoidosis, endophthalmitis, diabetes mellitus, myasthenia gravis
	CK-301	IgG1	N/A (ongoing)
	CS-1001	IgG4	Anemia, increased blood bilirubin, protein urine present, white blood cell count decreased, proteinuria
	SHR-1316	IgG4	N/A (ongoing)
	CBT-502	IgG1	N/A (ongoing)
	BGB-A333	IgG1 variant	N/A (ongoing)
PD-1	Nivolumab	IgG4	Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction, encephalitis, rash
	Pembrolizumab	IgG4	Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction
	Cemiplimab	IgG4	Cellulitis, pneumonitis, hypercalcemia, pleural effusion